Abstract:Background: 5q spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease. Objective: We aimed to assess the effects of nusinersen on motor function and electrophysiological parameters in adolescent and adult patients with 5q SMA. Methods: Patients with genetically confirmed 5q SMA were eligible for inclusion, and clinical data were collected at baseline (V1), 63 days (V4), 180 days (V5), and 300 days (V6). The efficacy of nusinersen was monitored by encompassing clinical assessments, including the Revised Upper Limb Module (RULM), Hammersmith Functional Motor Scale Expanded (HFMSE), 6-Minute Walk Test (6MWT), and percent-predicted Forced Vital Capacity in sitting position (FVC%) and Compound Muscle Action Potential (CMAP) amplitude. The patients were divided into "sitter" and "walker" subgroups according to motor function status. Results: 54 patients were screened, divided into "sitter" (N = 22) and "walker" (N = 32), with the mean age at baseline of 27.03 years (range 13-53 years). The HFMSE in the walker subgroup increased significantly from baseline to V4 (mean change +2.32-point, P = 0.004), V5 (+3.09, P = 0.004) and V6 (+4.21, P = 0.005). The patients in both the sitter and walker subgroup had no significant changes in mean RULM between V1 and the following time points. Significant increases in CMAP amplitudes were observed in both upper and lower limbs after treatment. Also, patients with RULM ≥ 36 points showed significant CMAP improvements. Our analysis predicted that patients with CMAP amplitudes of trapezius ≥ 1.76 mV were more likely to achieve significant motor function improvements. Conclusions: Nusinersen effectively improves motor function and electrophysiological data in adolescent and adult patients with SMA. This is the first report on the CMAP amplitude changes in the trapezius after treatment in patients with SMA. The CMAP values effectively compensate for the ceiling effect observed in the RULM, suggesting that CMAP could serve as an additional biomarker for evaluating treatment efficacy.

A Post-Marketing Surveillance Study of Nusinersen for Spinal Muscular Atrophy in Routine Medical Practice in China: Interim Results

Nusinersen Effectiveness and Safety in Pediatric Patients with 5Q-Spinal Muscular Atrophy: a Multi-Center Disease Registry in China

Study on the efficacy, safety, and biomarkers of nusinersen in type II and III spinal muscular atrophy in children

Safety Analysis of Laboratory Parameters in Paediatric Patients with Spinal Muscular Atrophy Treated with Nusinersen

Nusinersen treatment in adults with severe spinal muscular atrophy: A real-life retrospective observational cohort study

[Clinical efficacy of nusinersen sodium in the treatment of children with spinal muscular atrophy]

Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

An early Transcriptomic Investigation in Adult Patients with Spinal Muscular Atrophy Under Treatment with Nusinersen

Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database

Preliminary insights into RNA in CSF of pediatric SMA patients after 6 months of nusinersen

Effect of Nusinersen on Respiratory and Bulbar Function in Children with Spinal Muscular Atrophy: Real-World Experience from a Single Center

Profiling neuroinflammatory markers and response to nusinersen in paediatric spinal muscular atrophy

Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients

Proteomics profiling and machine learning in nusinersen-treated patients with spinal muscular atrophy

Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen

Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study

An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies

Long-term impact of nusinersen on motor and electrophysiological outcomes in adolescent and adult spinal muscular atrophy: insights from a multicenter retrospective study

Improvement in functional motor scores in patients with non-ambulatory spinal muscle atrophy during Nusinersen treatment in South Korea: a single center study

Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment